Figure 2
Effect of cardiotoxic drugs on hiPSC-CMs viability and GDF15 secretion and modes of action of applied drugs. (A) hiPSC-CMs viability after 48 h treatment with 20 cardiotoxic drugs. (B) Fold-change of GDF15 expression upon 48 h treatment with 20 cardiotoxic drugs and their reported modes of action. GDF15 expression upon treatment with 10 µM, sublethal drug concentrations and maximal GDF15 induction (from concentration series depicted in (C)). Mean fold-change of 4 biological replicates with a 95% confidence interval were normalized by DMSO-only control. (C) Drug-induced GDF15 expression for different drug concentrations. Fold-change of GDF15 protein concentration upon 48 h treatment with ten cardiotoxic drugs (marked with * in A and B). As the GDF15 concentrations induced by 1 µM idarubicin and 1 µM daunorubicin exceeded the upper limit of quantification, the maximum measurable concentration was used.
